Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

MLA

Stepien, Kimberly E., et al. “Comparison of Intravitreal Bevacizumab Followed by Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration.” Retina (Philadelphia, Pa.), vol. 29, no. 8, Sept. 2009, pp. 1067–73. EBSCOhost, https://doi.org/10.1097/IAE.0b013e3181b1bb06.

APA

Stepien, K. E., Rosenfeld, P. J., Puliafito, C. A., Feuer, W., Shi, W., Al-Attar, L., Dubovy, S. R., Murray, T. G., Davis, J. L., Lee, W.-H., Schwartz, S. G., Smiddy, W. E., Berrocal, A. M., & Flynn, H. W., Jr. (2009). Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina (Philadelphia, Pa.), 29(8), 1067–1073. https://doi.org/10.1097/IAE.0b013e3181b1bb06

Chicago

Stepien, Kimberly E, Philip J Rosenfeld, Carmen A Puliafito, William Feuer, Wei Shi, Luma Al-Attar, Sander R Dubovy, et al. 2009. “Comparison of Intravitreal Bevacizumab Followed by Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration.” Retina (Philadelphia, Pa.) 29 (8): 1067–73. doi:10.1097/IAE.0b013e3181b1bb06.